Long-term Impairment Attributable to Congenital Cytomegalovirus Infection: a Retrospective Cohort Study
Overview
Authors
Affiliations
Aim: This study aimed to estimate long-term impairment attributable to congenital cytomegalovirus infection (cCMV).
Method: This nationwide cohort study retrospectively assessed cCMV in children born in 2008 in the Netherlands, testing 31 484 stored neonatal dried blood spots. Extensive medical data of cCMV-positive children (n=133) and matched cCMV-negative comparison children (n=274) up to 6 years of age were analysed.
Results: Moderate to severe long-term impairment was diagnosed in 24.8% (33 out of 133) of all cCMV-positive children (53.8% in symptomatic, 17.8% in asymptomatic), compared with 12.0% (33 out of 274) of cCMV-negative children. Sensorineural hearing loss was seen only in five cCMV-positive children (3.8%). Developmental delays were diagnosed more often in cCMV-positive children than cCMV-negative children: motor (12.0% vs 1.5%), cognitive (6.0% vs 1.1%), and speech-language (16.5% vs 7.3%). Long-term impairment in multiple domains was more frequent in symptomatic (19.2%) and asymptomatic (8.4%) cCMV-positive children than cCMV-negative children (1.8%).
Interpretation: Children with cCMV were twice as likely to have long-term impairment up to the age of 6 years, especially developmental delays and sensorineural hearing loss, than cCMV-negative comparison children, with a risk difference of 12.8%. These insights into the risk of cCMV-associated impairment can help optimize care and stimulate preventive measures.
What This Paper Adds: Congenital cytomegalovirus infection (cCMV) leads to impairment in 25% of cases. Fifty per cent of children with cCMV symptoms at birth have long-term impairment. The risk difference of moderate to severe long-term impairment between children with and without cCMV is 13%, attributable to cCMV. cCMV leads to motor, cognitive, and speech-language developmental delay in children.
Katungye R, Musooko M, Sekikubo M, Mutabazi T, Kyohere M, Tusubira V Open Forum Infect Dis. 2025; 11(Suppl 3):S200-S205.
PMID: 40070698 PMC: 11891130. DOI: 10.1093/ofid/ofae604.
Congenital cytomegalovirus in eastern Uganda: prevalence and outcomes.
Okalany N, Engebretsen I, Mukunya D, Chebet M, Okello F, Weeks A BMC Pediatr. 2025; 25(1):179.
PMID: 40065261 PMC: 11895346. DOI: 10.1186/s12887-025-05518-7.
Ultrasound features of congenital cytomegalovirus infection in the first trimester: A case report.
Chen X, Zhang L, Bai L World J Clin Cases. 2025; 13(5):97629.
PMID: 39959771 PMC: 11606364. DOI: 10.12998/wjcc.v13.i5.97629.
A vaccine against cytomegalovirus: how close are we?.
Permar S, Schleiss M, Plotkin S J Clin Invest. 2025; 135(1).
PMID: 39744948 PMC: 11684802. DOI: 10.1172/JCI182317.
Pesch M, Brown K, Birath A, Demmler-Harrison G, Sapp C, Selleck A Otolaryngol Head Neck Surg. 2024; 172(2):728-733.
PMID: 39666828 PMC: 11773442. DOI: 10.1002/ohn.1079.